Streetbeat News

Products Services

VSTO

MNC Capital Partners has increased its acquisition offer for Vista Outdoor, Inc. (NYSE:VSTO) to $37.50 per share, valuing the company at approximately $3.0 billion. This offer is a 16% premium over Vista's last closing price and significantly higher than the initial offer made in February. The bid is not contingent on financing or CFIUS review, and MNC urges a quick response from Vista, highlighting benefits for shareholders and employees. Additionally, Vista's segment Revelyst acquired PinSeeker, enhancing its off-course golf and connectivity offerings. VSTO shares rose 0.37% to $32.38 following the news.

Portfolio Pulse from Akanksha Bakshi

March 25, 2024 | 2:18 pm

FCX

GOLD

NEM

The Biden administration announced a $475 million funding allocation for clean energy projects in the mining sector, targeting companies like Freeport-McMoRan (FCX), Barrick Gold (GOLD), and Newmont (NEM). This initiative aims to support communities affected by the energy transition, with each company pursuing unique projects and strategies. Freeport-McMoRan is focusing on a geothermal and battery storage project in Arizona, Barrick Gold is expanding into copper mining in Africa and the Middle East, and Newmont is streamlining operations post-Newcrest acquisition.

Portfolio Pulse from Stjepan Kalinic

March 25, 2024 | 2:18 pm

SMCI

JPMorgan has identified a tech stock, presumably SMCI, that has already tripled in value this year and is expected to continue its upward trajectory due to its significant role in the AI revolution. The endorsement from a major financial institution like JPMorgan suggests strong confidence in the company's future performance and its contributions to AI technology.

Portfolio Pulse from Happy Mohamed

March 25, 2024 | 1:49 pm

IVVD

The FDA granted emergency use authorization to Invivyd Inc's Pemgarda for COVID-19 prevention in individuals with immune compromise. Invivyd announced financial details, including a cash runway into Q4 2024, and shared interim data from the CANOPY Phase 3 trial of VYD222 (Pemgarda), showing promising results against COVID-19. However, IVVD shares dropped 13.20% to $3.79.

Portfolio Pulse from Vandana Singh

March 25, 2024 | 1:44 pm

CRWD

CrowdStrike (NASDAQ:CRWD) and HCLTech (NSE: HCLTECH) have announced a strategic partnership where HCLTech's managed detection and response (MDR) solutions will utilize CrowdStrike's AI-native Falcon XDR platform. This collaboration aims to enhance enterprise cybersecurity transformation, leveraging the Falcon platform's capabilities across various cybersecurity domains. The partnership is expected to address the increasing sophistication of cyberattacks and the cybersecurity skills gap by combining HCLTech's MDR expertise with CrowdStrike's technology.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 1:30 pm

BOSC

BOS Better Online Solutions Ltd. (BOS) received a €565,000 order for a robotic production line from an Israeli defense-industry customer, set for delivery in Q4 2024. This aligns with BOS' strategic growth plan focusing on the Israeli defense market.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 1:26 pm

LXRX

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced four presentations on sotagliflozin at the American College of Cardiology session, highlighting its efficacy in reducing stroke and heart attack risk among patients with type 2 diabetes, CKD, and high CV risk. The FDA approved sotagliflozin in 2023 for reducing cardiovascular death and hospitalization in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 1:25 pm

ESPR

Esperion Therapeutics Inc's (NASDAQ:ESPR) stock is trading higher after the FDA approved new label expansions for its drugs NEXLETOL and NEXLIZET, based on CLEAR Outcomes data. These expansions include indications for cardiovascular risk reduction and LDL-C lowering in primary and secondary prevention patients. The approvals make over 70 million patients eligible for these treatments. The company also anticipates a final determination from the European Medicines Agency on label expansions in Europe by the second quarter of 2024.

Portfolio Pulse from Vandana Singh

March 25, 2024 | 1:24 pm

BA

DBC

NVDA

PCG

On CNBC's 'Halftime Report Final Trades,' analysts recommended Boeing (BA), PG&E (PCG), Invesco DB Commodity Index Tracking Fund (DBC), and NVIDIA (NVDA). Boeing faces cash outflow concerns due to regulatory scrutiny. PG&E raised its FY24 earnings outlook after better-than-expected Q4 earnings. NVIDIA received a price target increase from UBS and unveiled new products at its GTC event. The stocks showed mixed performance on Friday, with BA and NVDA gaining, while PCG and DBC fell.

Portfolio Pulse from Avi Kapoor

March 25, 2024 | 1:17 pm

TFFP

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) announced its Phase 2 study of Tacrolimus Inhalation Powder for lung transplant rejection prevention will be presented at the ISHLT 2024 Meeting. The study suggests that this method could offer effective immunosuppression with lower systemic exposure than oral tacrolimus. The presentation will detail the trial's safety, tolerability, efficacy, and pharmacokinetics in patients with significant renal impairment.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 1:16 pm